Determinants of single‑pass specimen adequacy in endobronchial ultrasound-guided transbronchial needle aspiration: a real-world study Authors: Yajuan Qian, Yongkang Huang, Xiaoliang Zhu, Yong Yu, Ziyan Du, Zengli Zhang Published: 2026 ABSTRACT BackgroundAlthough endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) diagnostic yield has been widely studied, factors influencing specimen adequacy from a single puncture remain unclear. This study aimed to identify factors associated with the specimen adequacy of a single EBUS‑TBNA puncture to inform and refine procedural strategies.MethodsThis single-center observational study enrolled consecutive patients undergoing EBUS-TBNA. Puncture-level data were collected, and the primary outcome was the single-pass specimen adequacy rate, assessed using the Macroscopic On-site Specimen Evaluation (MOSE) scoring system. Evaluated variables included procedure-related factors (needle pathway, operator experience), lymph-node characteristics (station, size, N stage, presence of computed tomography (CT) hypodense areas), and patient characteristics. A cumulative link mixed model (CLMM) was used to identify independent predictors of specimen adequacy.ResultsA total of 426 lymph nodes (636 punctures) from 219 patients were analyzed. The median MOSE score was 2 [1, 4] and the median puncture attempts was 1 [1, 2]. In univariate analyses, lymph node size, malignant pathology, and lymph node station were associated with specimen adequacy, whereas needle pathway (central vs. peripheral), N stage, the presence of a hypodense area, and operator experience were not significant predictors (P>0.05). Multivariate analysis identified lymph node station and a final diagnosis of malignant pathology as independent predictors of specimen adequacy (P<0.05).ConclusionsIn this study, specimen adequacy from a single EBUS‑TBNA puncture appeared to be more closely related to malignancy and lymph node station. These findings indicate that disease‑related factors may influence single‑pass yield; however, additional studies are required to validate these results and determine their applicability across different clinical settings. Highlight box Key findings • Specimen adequacy from a single endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) puncture was independently predicted by lymph node station and a final diagnosis of malignancy. Procedure-related factors, including needle pathway (central vs. peripheral) and operator experience, were not significantly associated with single‑pass adequacy in this real-world study. What is known and what is new? • EBUS-TBNA is a standard technique for mediastinal and hilar lymph node sampling, with specimen adequacy influenced by a combination of technical, operator, and lesion-specific factors. • This study suggests that disease-related factors, specifically malignancy and lymph node station, may be more critical determinants of single‑pass specimen adequacy than modifiable procedural factors such as operator experience or needle pathway. What is the implication, and what should change now? • The findings imply that optimizing single‑pass yield may require greater emphasis on patient and lesion characteristics rather than solely focusing on technical maneuvers. Further prospective validation is needed before these results can be translated into refined procedural protocols across diverse clinical settings. Introduction Mediastinal lymphadenopathy is an important imaging manifestation of thoracic diseases and generally reflects reactive enlargement of lymph nodes in response to infectious, inflammatory, or neoplastic stimuli. Rather than representing an independent disease entity, it typically signals an underlying pathological process. The etiologies are diverse and include infectious diseases (such as tuberculosis and certain fungal infections), inflammatory or immune mediated disorders (such as sarcoidosis), and malignancies (including lymphoma, lung cancer, and other metastatic tumors). In addition, occupational exposures, drug reactions, and post-infectious reactive hyperplasia may also contribute to lymph node enlargement (1). Given the heterogeneity of potential causes and their markedly different clinical implications, imaging assessment requires a comprehensive evaluation of lymph node distribution, morphology, density, and metabolic characteristics, and often necessitates cytological or histological sampling for definitive diagnosis (2,3). Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive diagnostic modality that employs a convex ultrasound probe at the bronchoscope tip to visualize peribronchial structures in real time, enabling precise needle aspiration of mediastinal and hilar lymph nodes under direct ultrasound guidance (4). Compared with conventional transbronchial needle aspiration (cTBNA) performed without ultrasound, EBUS-TBNA substantially improves targeting accuracy and sampling success. It has demonstrated superior sensitivity and specificity in mediastinal staging of lung cancer (5), diagnosis of lymphoma, and differentiation between benign and malignant lymphadenopathy, thereby reducing the need for surgical mediastinoscopy (6,7). As a result, its clinical use has expanded rapidly. Despite these advantages, EBUS-TBNA has several limitations. The equipment is costly, and operators must undergo extensive training to achieve proficiency (8). To enhance diagnostic yield, expert consensus generally recommends performing at least three needle passes per target lymph node (9). However, when multiple lymph nodes or lesions require sampling, the cumulative number of punctures can significantly prolong the procedure, potentially increasing patient discomfort, procedural complications (10), and anesthesia-related risks (11). Although a single‑pass may occasionally provide an adequate specimen, existing studies have largely focused on overall diagnostic yield and have not systematically examined factors influencing the adequacy of specimens obtained from a single‑pass. Moreover, operators—particularly those who are early in their learning curve—often rely on empirical judgment when selecting the optimal lymph node for sampling and determining the most effective puncture strategy. Therefore, this study aimed to systematically identify the key factors associated with specimen adequacy from a single EBUS-TBNA puncture, with the goal of optimizing procedural workflow, improving single‑pass efficiency, reducing unnecessary repeat punctures, and minimizing patient related risks. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0835/rc). Methods Study design This was a single-center observational study. All procedures were performed as part of routine clinical care, and no additional interventions were introduced for research purposes. The study protocol was reviewed and approved by the Ethics Committee of The Second Affiliated Hospital of Soochow University (approval No. JD-HG-2024-097). Informed consent was taken from all the patients. To ensure confidentiality, all patient data were anonymized before analysis. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Study population Consecutive adult patients who underwent EBUS-TBNA at The Second Affiliated Hospital of Soochow University between September 2024 and January 2026 were included. Patients were excluded if any of the following criteria were met: Fusion between the lymph node and an adjacent pulmonary lesion, making clear delineation impossible. Fusion between the lymph node and an adjacent pulmonary lesion, making clear delineation impossible. The procedure targeted only pulmonary lesions without sampling any lymph nodes. The procedure targeted only pulmonary lesions without sampling any lymph nodes. The puncture specimen was deemed invalid due to technical issues (e.g., ≤10 aspiration strokes because of significant bleeding) or failure to successfully enter the target lymph node. The puncture specimen was deemed invalid due to technical issues (e.g., ≤10 aspiration strokes because of significant bleeding) or failure to successfully enter the target lymph node. Operational procedure All procedures were performed under general anesthesia. Target lymph nodes were selected by the clinical team based on each patient’s diagnostic needs. An Olympus 260 or 290 series bronchoscope equipped with a 22-gauge needle was used. A uniform negative pressure was applied using a 20 mL syringe. After needle insertion, a minimum of 15 to-and-fro aspiration strokes was performed. Following each needle withdrawal, the stylet was used to expel the specimen into a container filled with 10% neutral buffered formalin. Macroscopic specimen quality was jointly assessed by the operator and a second respiratory physician using the Macroscopic On-site Specimen Evaluation (MOSE) scoring system. The score reflects the cumulative length and continuity of string-like tissue fragments, defined as follows: ❖ 4 points: long, continuous tissue strips with a cumulative length >30 mm, appearing as a “ball of yarn” in fixative. ❖ 4 points: long, continuous tissue strips with a cumulative length >30 mm, appearing as a “ball of yarn” in fixative. ❖ 3 points: long, continuous tissue strips with a cumulative length of 20–30 mm. ❖ 3 points: long, continuous tissue strips with a cumulative length of 20–30 mm. ❖ 2 points: shorter tissue strips with a cumulative length of 10–20 mm. ❖ 2 points: shorter tissue strips with a cumulative length of 10–20 mm. ❖ 1 point: short, fragmented, oval-shaped solid pieces with a cumulative length <10 mm, or specimens composed predominantly of blood clot. ❖ 1 point: short, fragmented, oval-shaped solid pieces with a cumulative length <10 mm, or specimens composed predominantly of blood clot. ❖ 0 points: no macroscopically visible solid material. ❖ 0 points: no macroscopically visible solid material. Observational metrics Primary outcome: single‑pass specimen adequacy, defined as a MOSE score described above (ordinal scale 0–4). Primary outcome: single‑pass specimen adequacy, defined as a MOSE score described above (ordinal scale 0–4). Procedure-related variables:Needle pathway (central zone: within the central one third of the lymph node; peripheral zone).Operator experience (skilled: >6 months of practice and >100 cumulative procedures; novice).Number of punctures performed per target lymph node. Procedure-related variables: Needle pathway (central zone: within the central one third of the lymph node; peripheral zone). Needle pathway (central zone: within the central one third of the lymph node; peripheral zone). Operator experience (skilled: >6 months of practice and >100 cumulative procedures; novice). Operator experience (skilled: >6 months of practice and >100 cumulative procedures; novice). Number of punctures performed per target lymph node. Number of punctures performed per target lymph node. Lymph node-related variables:Lymph node station [classified according to the International Association for the Study of Lung Cancer (IASLC) map].Short axis diameter on computed tomography (CT) imaging.Presence of a distinct liquefactive necrotic (hypodense) area on contrast-enhanced CT judged by two radiologists.Shortest distance from the lymph node to the airway wall on ultrasound.Final pathological diagnosis (benign vs. malignant) and N-stage (recorded as NA for non-neoplastic conditions; for suspected tumors, staging followed IASLC definitions). Lymph node-related variables: Lymph node station [classified according to the International Association for the Study of Lung Cancer (IASLC) map]. Lymph node station [classified according to the International Association for the Study of Lung Cancer (IASLC) map]. Short axis diameter on computed tomography (CT) imaging. Short axis diameter on computed tomography (CT) imaging. Presence of a distinct liquefactive necrotic (hypodense) area on contrast-enhanced CT judged by two radiologists. Presence of a distinct liquefactive necrotic (hypodense) area on contrast-enhanced CT judged by two radiologists. Shortest distance from the lymph node to the airway wall on ultrasound. Shortest distance from the lymph node to the airway wall on ultrasound. Final pathological diagnosis (benign vs. malignant) and N-stage (recorded as NA for non-neoplastic conditions; for suspected tumors, staging followed IASLC definitions). Final pathological diagnosis (benign vs. malignant) and N-stage (recorded as NA for non-neoplastic conditions; for suspected tumors, staging followed IASLC definitions). Patient variables: age, sex, body mass index (BMI), and recent anti-cancer treatments (chemotherapy and/or immunotherapy within 3 months). Patient variables: age, sex, body mass index (BMI), and recent anti-cancer treatments (chemotherapy and/or immunotherapy within 3 months). Statistical analysis Statistical analyses were performed using R software (version 4.5.2). Continuous variables were presented as mean ± standard deviation or median (lower interquartile, higher interquartile), and categorical variables as frequency (percentage). Intergroup comparisons were conducted using the Chi‑squared test, Fisher’s exact test, t‑test, or Mann‑Whitney U test, as appropriate. To identify independent predictors of specimen adequacy, we performed a cumulative link mixed model (CLMM) for ordinal outcomes. This model accounted for the hierarchical data structure (multiple punctures nested within lymph nodes, and lymph nodes nested within patients) by including random intercepts for patients and for lymph nodes within patients, thus utilizing all 636 puncture attempts. Candidate predictors were selected based on clinical relevance and univariable analysis (P<0.05). The proportional odds assumption was evaluated. Results are reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). A two‑sided P<0.05 was considered statistically significant. Results Study population and procedural overview A total of 248 patients were initially screened, of whom 219 met the inclusion criteria and were included in the final analysis (Figure 1). The mean age was 64±11 years, and 66 patients (30.1%) were female. Pre-procedural clinical impressions included suspected malignancy in 174 patients (79.5%), suspected sarcoidosis in 19 (8.7%), suspected tuberculosis in 8 (3.7%), and other conditions in 17 (7.8%). Across all patients, 636 punctures were performed on 426 lymph nodes and median number of punctures was 1 [1, 2], and the median MOSE score was 2 [1, 4]. Baseline characteristics of patients and lymph nodes are summarized in Table 1. Study flow. EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration. Table 1Characteristics of patients, lymph nodes, and puncturesVariableValueAge (years)64±11Sex (female)66 (30.1)BMI (kg/m2)23.27±3.16Pre-procedural diagnosis Suspected cancer174 (79.5) Suspected sarcoidosis19 (8.7) Suspected tuberculosis8 (3.7) Others7 (7.8)Lymph node station 11L43 (10.1) 11R80 (18.8) 2L/4L46 (10.8) 2R/4R126 (29.6) 7124 (29.1) Others7 (1.6)Short‑axis diameters (mm)13.5 [10.6, 18.4]Lymph node enlarged344 (80.8)Puncture attempts1 [1, 2]Puncture trajectory (central)421 (66.2)Skilled operator246 (38.7)MOSE score2 [1, 4]Data are presented as mean ± SD, n (%), or median [IQR]. Patients N=219, nodes N=426, punctures N=636. BMI, body mass index; IQR, interquartile range; MOSE, Macroscopic On‑site Specimen Evaluation; SD, standard deviation. Characteristics of patients, lymph nodes, and punctures Data are presented as mean ± SD, n (%), or median [IQR]. Patients N=219, nodes N=426, punctures N=636. BMI, body mass index; IQR, interquartile range; MOSE, Macroscopic On‑site Specimen Evaluation; SD, standard deviation. Influence of needle pathway on specimen adequacy To evaluate the effect of needle pathway (central vs. peripheral), two complementary analyses were conducted. First, using individual puncture events as the analytical unit, a CLMM demonstrated that central punctures were associated with a lower MOSE score compared with peripheral punctures. However, this difference did not reach statistical significance [odds ratio (OR) =0.731; 95% CI: 0.515 to 1.038; P=0.08]. Second, using the lymph node as the analytical unit, nodes that underwent both central and peripheral punctures were identified. For each node, the highest MOSE score obtained via each pathway was compared. The Wilcoxon signed rank test revealed no significant difference between pathways [median difference =0 (interquartile range, IQR, 2); P=0.31] (Figure 2A). Puncture trajectory and MOSE score. (A) Comparison of highest MOSE scores between central and peripheral punctures in the same lymph nodes. (B) Impact of needle pathway switch on specimen quality improvement after suboptimal initial puncture. MOSE, Macroscopic On-site Specimen Evaluation; NS, not significant. Additionally, we assessed whether switching the needle pathway improved specimen quality after an initial suboptimal puncture (defined as a MOSE score increment <2 between consecutive passes). The median MOSE score increment for subsequent punctures was −0.5 (IQR, 2) when the original pathway was maintained and 0 (IQR, 1.75) when the pathway was switched. The difference between groups was not statistically significant (Figure 2B). Influence of lymph node characteristics on specimen adequacy Lymph node station Lymph nodes were categorized according to the IASLC map (2L/4L, 2R/4R, 11L, 11R, station 7, and others). Compared to station 7, station 11R (OR =0.515; 95% CI: 0.301 to 0.868; P=0.01) and station 2R/4R (OR =0.451; 95% CI: 0.280 to 0.726; P=0.001) were associated with lower sample adequacy, no significant differences in specimen adequacy rates were observed among station 11L, 2L/4L and others (P>0.05). N stage Compared to N1 lymph nodes, N2 lymph nodes showed similar sample adequacy (OR =0.964; 95% CI: 0.609 to 1.526; P=0.88) whereas N3 nodes (OR =0.529; 95% CI: 0.284 to 0.985; P=0.045) and those suspected non-malignancy (NA) (OR =0.526; 95% CI: 0.280 to 0.726; P=0.001) had lower adequacy rate. Lymph node size and distance Both long axis and short axis diameters were positively correlated with MOSE scores (P<0.01). Using a short axis diameter ≥10 mm as the threshold for enlargement, enlarged nodes did not have a higher adequacy rate than non-enlarged nodes (OR =0.981; 95% CI: 0.604 to 1.594; P=0.94). The distance between lymph nodes and the airway did not significantly affect the MOSE score (OR =1.055; 95% CI: 0.9194 to 1.211; P=0.07). Hypodense area The presence of a distinct hypodense (necrotic) region on CT imaging was not significantly associated with specimen adequacy (OR =0.973; 95% CI: 0.610 to 1.533; P=0.91). These findings are summarized in Table 2. Table 2Univariate analysis of factors associated with specimen adequacyVariateReferenceOR (95% CI)P valueAge–0.996 (0.978–1.016)0.72Sex (female)Male0.938 (0.599–1.471)0.78BMI–0.975 (0.913–1.04)0.44Malignant pathology (yes)No2.657 (1.733–4.074)<0.001*Anti-cancer treatment (yes)No0.622 (0.287–1.349)0.23Anti-cancer treatment (NA)No0.535 (0.267–1.074)0.08Lymph node station (11L)70.675 (0.357–1.277)0.23Lymph node station (11R)70.515 (0.306–0.868)0.01*Lymph node station (2L/4L)70.675 (0.349–1.307)0.24Lymph node station (2R/4R)70.451 (0.28–0.726)0.001*Lymph node station (others)70.744 (0.183–3.017)0.68N stage (N2)N10.964 (0.609–1.526)0.88N stage (N3)N10.529 (0.284–0.985)0.045*N stage (NA)N10.526 (0.282–0.983)0.044*Short axis diameters (mm)–1.048 (1.013–1.083)0.006*Long axis diameters (mm)–1.044 (1.016–1.074)0.002*Lymph node enlarged (yes)No0.981 (0.604–1.594)0.94Lymph node-airway interval (mm)–1.055 (0.919–1.211)0.45Hypodense area (yes)No0.973 (0.61–1.553)0.91Puncture trajectory (central)Peripheral0.731 (0.515–1.038)0.08Operator (skilled)Non-skilled0.95 (0.627–1.44)0.81*, P<0.05. BMI, body mass index; CI, confidence interval; N, nodal; NA, not applicable; OR, odds ratio. Univariate analysis of factors associated with specimen adequacy *, P<0.05. BMI, body mass index; CI, confidence interval; N, nodal; NA, not applicable; OR, odds ratio. Influence of patient characteristics on specimen adequacy Patient sex, age, BMI and whether the operator was skilled were not significantly associated with specimen adequacy. Lymph nodes with a final pathological diagnosis of malignancy demonstrated significantly higher adequacy rates than benign nodes (OR =2.657; 95% CI: 1.722 to 4.074; P<0.001). These results are summarized in Table 2. Multivariate analysis of factors influencing specimen adequacy Variables identified as significant in univariate analyses or clinically relevant were included in a multivariate ordinal CLMM model (Figure 3). After adjustment for potential confounders, station 11R (adjusted OR =0.355; 95% CI: 0.165 to 0.765; P=0.008) and station 2R/4R (adjusted OR =0.519; 95% CI: 0.316 to 0.851; P=0.009) remained associated with lower specimen adequacy. Differences between N1 and N3 lymph nodes (adjusted OR =0.553; 95% CI: 0.241 to 1.267; P=0.16) and those suspected non-malignancy (NA) (adjusted OR =0.495; 95% CI: 0.213 to 1.149; P=0.10) did not reach a significance. Lymph nodes with a final pathological diagnosis of malignancy demonstrated significantly higher adequacy rates than benign nodes (OR =2.028; 95% CI: 1.210 to 3.398; P=0.007). Short-axis diameters of lymph node, needle pathway, sex, age and enlarged nodes and presence of a hypodense area did not demonstrate independent associations in the multivariate model. Multivariate analysis of factors influencing specimen adequacy. *, P<0.05. BMI, body mass index; CI, confidence interval; N, nodal; NA, not applicable; OR, odds ratio. Discussion This study systematically examined multiple factors that may influence the specimen adequacy rate of a single EBUS-TBNA puncture. In contrast to most prior studies that emphasize final diagnostic yield, we focused on the macroscopic quality of tissue obtained from each individual puncture. This approach has direct clinical relevance, as sufficient samples facilitate subsequent diagnosis. Identifying the factors that can determine the sample adequacy can inform real time intraoperative decision-making and help optimize puncture strategies to minimize unnecessary repeat passes. MOSE and ROSE represent two complementary approaches for on-site adequacy assessment, with MOSE relying on macroscopic specimen evaluation and ROSE based on microscopic cytological examination. Although MOSE score and tumor cellularity are not equivalent, recent studies showed the two approaches have similar diagnostic yield, accuracy, sensitivity and specificity in endoscopic ultrasound (EUS)-guided sampling (12,13). Compared with ROSE, which requires a cytopathologist or trained evaluator, MOSE is easier to implement in routine practice and was therefore adopted as the adequacy indicator in the present study. We observed that lymph node station, lymph node size, malignant pathology, and N stage were associated with differences in specimen adequacy in univariate analysis. In multivariate analysis, only lymph node station and malignant pathology remained independent factors. Conversely, several factors traditionally emphasized in clinical practice—such as needle pathway (central vs. peripheral) and CT features including hypodense areas—did not independently affect specimen adequacy after adjustment for confounders. These findings challenge certain empirical assumptions and can be interpreted through both technical and biological perspectives. When selecting the puncture trajectory, elastography or validated EBUS-based scoring systems (e.g., the Canada lymph node score) may help improve diagnostic yield (14,15). However, these techniques were not routinely available in our clinical setting, and the choice between central and peripheral puncture trajectories largely depended on operator preference, for which clinical opinions remain inconsistent. Some advocate central puncture to maximize the length of tissue traversed, whereas others prefer peripheral puncture due to concerns about central necrosis. Our results demonstrated no significant difference in adequacy between the two pathways. Similarly, the presence of a CT-defined hypodense area, often interpreted as necrosis, did not reduce specimen adequacy. Several factors may explain these observations. First, lymph nodes with central necrosis are typically larger, and the necrotic core is usually surrounded by a rim of viable reactive or tumoral tissue (16,17). A needle directed centrally must pass through this solid rim, allowing adequate tissue acquisition before reaching the necrotic zone. Second, real-time EBUS imaging enables operators to avoid areas of complete cavitation and to target regions with preserved echogenicity. Even partially necrotic areas may contain solid components amenable to aspiration. Third, metastatic lymph nodes are often microscopically heterogeneous; viable tumor clusters may be present in both central and peripheral regions. Thus, as long as a solid-appearing region is targeted under ultrasound guidance, the macroscopic needle trajectory may be less critical than traditionally assumed. A published systematic review reported that the number of procedures required to overcome the initial EBUS learning curve ranged from 10 to 100 across studies, with mean estimates of approximately 37–44 procedures (18). In the present study, operator experience was pragmatically defined according to cumulative procedural volume (>100 procedures) and duration of practice (>6 months), based on institutional training standards and prior literature on the EBUS learning curve. Although pathologists’ proficiency independently affected the diagnostic accuracy of EBUSTBNA in previous study (19), there was no significant difference in sample adequacy between skilled and non‑skilled operators (adjusted OR =1.23, 95% CI: 0.80–1.90). Lymph node size was associated with specimen adequacy in univariate analysis, but using a typical short-axis diameter ≥10 mm as the threshold for enlargement, it did not demonstrate that enlarged lymph nodes yielded higher specimen adequacy. Moreover, short axis diameter was not independently associated with specimen adequacy in the multivariate model. Only lymph node stations and malignant pathology independently predicted higher specimen adequacy. This likely reflects intrinsic biological characteristics. Compared to benign reactive or fibrotic lymph nodes, malignant lymph nodes often contain clusters of tumor cells that may appear loosely cohesive due to epithelial-mesenchymal transition, loss of Ecadherin, and stromal remodeling (20,21), thus increasing the likelihood of obtaining adequate samples. In contrast, recent antitumor therapy tend to predict reduced adequacy though the significance was not reached (OR =0.622, 95% CI: 0.287–1.349), likely due to therapy induced necrosis, fibrosis (22), or inflammatory changes (23) that alter tissue consistency and reduce cellular yield. The present study shifts the evaluative focus from whether a final diagnosis is ultimately achieved to whether each individual puncture yields an adequate specimen. This perspective provides practical evidence to refine EBUS-TBNA technique. Our findings indicate that, with the advantage of real-time ultrasound guidance, operators need not overemphasize choosing specific pathways. Instead, greater emphasis should be placed on identifying optimal lymph node and accurately targeting solid components within the lymph node. This study has several limitations. First, the relatively small sample size and the predominance of lung cancer among malignant cases limited detailed subgroup analyses, particularly for lymphoma and metastatic carcinoma. In addition, as a single-center real-world study, the findings may have been influenced by pretest probability and lymph node selection bias, potentially limiting generalizability. Second, although the MOSE scoring system is practical for routine procedures, macroscopic assessment cannot fully substitute for microscopic cytological evaluation. Third, because universally accepted criteria for several procedural indicators are lacking, institutional standards were adopted, which may affect reproducibility across centers. Fourth, advanced ultrasonographic features such as elastography-assessed nodal stiffness and texture were not evaluated because of equipment limitations. Finally, although this study aimed to identify determinants of single-pass specimen adequacy, the feasibility and diagnostic safety of a routine single-puncture strategy require further validation in prospective multicenter studies. Conclusions This observational study demonstrates that the primary determinants of specimen adequacy from a single EBUS-TBNA puncture are related to the intrinsic characteristics of the lymph node—specifically malignancy and lymph node station—rather than technical factors such as needle pathway selection. These findings underscore the central value of EBUS as a real-time imaging modality that enables precise targeting of solid nodal components. Operators, particularly those early in their learning curve, should focus less on adhering to a fixed puncture trajectory and more on developing the ability to interpret intranodal sonographic features. Integrating these skills with pre-procedural clinical staging information may facilitate more individualized, efficient, and effective sampling strategies. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0835/prf